Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22375325 | 0.86 | TRPA1 (0.40) | MAPTFFAR1FFAR4ARALDH1A1 | |
| SCHEMBL15250773 | 0.82 | SLC18A1 (0.37) | FFAR1FFAR4ARALDH1A1HPGD | |
| SCHEMBL631579 | 0.81 | MAPT (0.46) | MAPTLMNAARALDH1A1HPGD | |
| SCHEMBL29659123 | 0.81 | MAPT (0.46) | MAPTLMNAARALDH1A1HPGD | |
| SCHEMBL1800645 | 0.78 | KMT2A (0.50) | MAPTLMNAALDH1A1RECQLHSD17B10 | |
| SCHEMBL27446134 | 0.77 | TDP1 (0.38) | MAPTFFAR1FFAR4LMNAAR | |
| SCHEMBL3397984 | 0.76 | RAPGEF4 (0.50) | MAPTALDH1A1HPGDPOLBKDM4E | |
| SCHEMBL20226648 | 0.76 | ALDH1A1 (0.45) | MAPTFFAR4LMNAARALDH1A1 | |
| SCHEMBL8292658 | 0.76 | ABL1 (0.40) | MAPTLMNAARALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL3395950 | 0.74 | RAPGEF4 (0.49) | MAPTALDH1A1HPGDPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110815-B1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEV INC (CN) | 2020-02-19 | — | — | EP | disclosed |
| US-9783539-B2 | Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-10-10 | — | — | US | disclosed |
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3110815-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | Jiangsu Ascentage Biomed Development Inc. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127629-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066761-A1 | INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS | ALK, BCL6, BCL6B | MAPT 1973/4885FFAR1 2573/4885FFAR4 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.